Until further human studies yield more conclusive results, the FDA recommends that users be advised of the potential risks. However, current practice by UK  dermatologists  is not to consider this a significant real concern and they are increasingly recommending the use of these new drugs. Interactions
Also like cyclosporin, it has a wide range of interactions. Tacrolimus is primarily metabolised by the cytochrome P450 system of liver enzymes, and there are many substances that interact with this system and induce or inhibit the systems metabolic activity.Interactions include that with grapefruit which increases tacrolimus plasma concentrations. As infections are a major cause of morbidity and mortality in the post-transplant patient, the most commonly reported interactions include interactions with anti-microbial drugs. Macrolide antibiotics including erythromycin and clarithromycin, as well as several of the newer classes of antifungals, especially of the azole class (fluconazole, voriconazole), increase tacrolimus levels by competing for cytochrome enzymes. Pharmacology
Mechanism of action
Tacrolimus is a macrolide calcineurin inhibitor. In T-cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. Calcineurin then dephosphorylates the transcription factor nuclear factor of activated T-cells (NF-AT), which moves to the nucleus of the T-cell and increases the activity of genes coding for IL-2 and related cytokines. Tacrolimus prevents the dephosphorylation of NF-AT.In detail, tacrolimus reduces peptidylprolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein), creating a new complex. This FKBP12–FK506 complex interacts with and inhibits calcineurin, thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.
Chest radiographs show areas of opacity due to fibrosis of the pulmonary parenchyma.Another form of diagnosis is observing patient symptoms throughout their work shift. Patients with byssinosis due to dust inhalation will experience adverse symptoms when they being their work shift on Monday which is where the term Monday Fever comes in. Treatment
There is currently no official form of diagnosing an individual with byssinosis. Affected workers should be offered alternative employment. Employers in the manufacturing and textile industry should take preventative measures to ensure workers are not exposed to excessive dust and cotton during their work shifts as this is the main cause of byssinosis exposure. Continued exposure leads to development of persistent symptoms and progressive decline in FEV1. Dust control measures can also help reduce the risk of textile workers developing byssinosis.Educational content aimed to raise awareness about byssinosis and other occupational lung diseases can be useful to inform workers and managers in textile industry as well as unions, and other health professionals. Educational content should be based on signs and symptoms of byssinosis as well as other diagnostic measures. See also
Cotton Production
Textile manufacturing
Respiratory Diseases
LCIM

Notes and References
Notes
References
Further reading
Snyder, Rachel Louise (2007). Fugitive Denim: A Moving Story of People and Pants in the Borderless World of Global Trade. W. W. Norton. ISBN 978-0-393-06180-2. External links

Byssinosis: MedlinePlus Medical Encyclopedia (NIH)
Work-Related Lung Disease Surveillance System (eWoRLD): Work-Related Respiratory Diseases | CDC/NIOSH